Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Herbalife (HLF – Research Report), Alignment Healthcare (ALHC – Research Report) and Vaxcyte (PCVX – Research Report).
Herbalife (HLF)
Bank of America Securities analyst Anna Lizzul maintained a Sell rating on Herbalife today and set a price target of $8.00. The company’s shares closed last Friday at $10.80.
According to TipRanks.com, Lizzul is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Herbalife with a $11.33 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Alignment Healthcare (ALHC)
In a report released today, Adam Ron from Bank of America Securities maintained a Hold rating on Alignment Healthcare. The company’s shares closed last Friday at $7.10.
According to TipRanks.com, Ron is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alignment Healthcare with a $7.63 average price target, which is a 9.2% upside from current levels. In a report issued on May 3, Stephens also maintained a Hold rating on the stock with a $7.00 price target.
Vaxcyte (PCVX)
In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Vaxcyte. The company’s shares closed last Friday at $75.12.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
Vaxcyte has an analyst consensus of Strong Buy, with a price target consensus of $103.00, a 36.5% upside from current levels. In a report issued on May 8, Leerink Partners also reiterated a Buy rating on the stock with a $106.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HLF:
- Herbalife’s (NYSE:HLF) Restructuring Efforts May Be Bearing Fruit
- Herbalife Shareholders Decide on Board and Incentives at AGM
- Herbalife rasies FY24 adjusted EBITDA view to $550M-$590M from $540M-$580M
- Herbalife sees Q2 adjusted EBITDA $140M-$160M vs. $169.6M y/y
- Herbalife reports Q1 EPS 49c, consensus 35c
